BBIXF:OTC-Bonus BioGroup Ltd (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.04

Change

0.00 (0.00)%

Market Cap

USD 0.05B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NONOF Novo Nordisk A/S

-2.97 (-2.05%)

USD 598.54B
CSLLY CSL Ltd

-0.12 (-0.13%)

USD 91.15B
CMXHF CSL Limited

-3.50 (-1.82%)

USD 88.48B
UCBJF UCB SA

N/A

USD 26.91B
UCBJY UCB SA ADR

+0.62 (+0.85%)

USD 26.37B
ARGNF argenx SE

N/A

USD 22.41B
GNMSF Genmab A/S

-7.49 (-2.80%)

USD 17.89B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 6.87B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 6.83B
REGMF RemeGen Co. Ltd

N/A

USD 6.81B

ETFs Containing BBIXF

QCLN:LSE First Trust Nasdaq Clean .. 6.97 % 0.00 %

-27.40 (-2.96%)

USD 0.01B
QCLU:LSE First Trust Nasdaq® Clea.. 6.97 % 0.00 %

-0.43 (-2.96%)

USD 0.01B
VNSE Natixis ETF Trust II - Na.. 4.07 % 0.00 %

-0.11 (-2.96%)

USD 0.03B
FHQ:CA First Trust AlphaDEX US T.. 1.80 % 0.77 %

-0.36 (-2.96%)

CAD 0.02B
FHQ-F:CA First Trust AlphaDEX U.S... 1.80 % 0.00 %

N/A

CAD 0.03B
MIDF 1.54 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 100.00% 92% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 100.00% 92% A 93% A
Trailing 12 Months  
Capital Gain 33.33% 83% B 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.33% 83% B 80% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 360.88% 88% B+ 92% A
Dividend Return 360.88% 88% B+ 92% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 2,441.19% 10% F 6% D-
Risk Adjusted Return 14.78% 64% D 49% F
Market Capitalization 0.05B 68% D+ 52% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.